Advent Life Sciences Becomes Latest Partner of One Nucleus

Press Release:

 

Advent Life Sciences Becomes Latest Partner of One Nucleus

Cambridge and London UK: 12th March 2021

Advent Life Sciences, one of the sector’s leading Trans-Atlantic venture investors has become the latest Partner to join One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the Partner and One Nucleus members.

Shahzad Malik, General Partner, Advent Life Sciences commented ‘Advent is committed to investing in outstanding, early-stage science and to establish and nurture innovative companies in the UK, Europe and US. We greatly value partnerships in supporting this, as exemplified by the our new Advent-Harrington Impact Fund, in conjunction with the transatlantic not-for-profit drug development group, Harrington Discovery Institute. Joining the Partner Programme brings further opportunities to our multinational portfolio of companies available through One Nucleus membership, and leveraging that ecosystem as they grow.’

Tony Jones, CEO of One Nucleus expands further ‘We are delighted to welcome Advent Life Sciences to the One Nucleus Partner Programme. Their track record of funding and nurturing high growth Life Science companies illustrates the value to our members and wider network of engaging them and their portfolio. One Nucleus is entirely focussed on how we bring great innovation, leadership and investment together to enable translation of world class science to patient benefit and returns for all stakeholders. Advent Life Sciences bring immense expertise, connectivity and capacity to help us in that endeavour.’

ENDS

About Advent Life Sciences
Advent Life Sciences founds and invests in early- and mid-stage life sciences companies that have a first- or best-in-class approach to unmet medical needs. The investing team consists of experienced professionals, each with extensive scientific, medical and operational experience, a long-standing record of entrepreneurial and investment success in the US and Europe and is particularly focused on supporting entrepreneurs and founders to take innovative new medical entities from concept to approval. The firm invests in a range of sectors within life sciences, principally drug discovery, enabling technologies and med tech, always with an emphasis on innovative, paradigm-changing approaches. Advent Life Sciences has a presence in the UK, US and France. For more information, please visit www.AdventLS.com

About One Nucleus
Established in 1997, One Nucleus is an award winning not-for-profit Life Sciences & Healthcare membership organisation centred on the Greater London-Cambridge-East of
England corridor. Headquartered in Cambridge, at the heart of Europe’s largest Life Sciences & Healthcare cluster, we support those institutions, companies and individuals undertaking activity in or with the above region.

Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximise their performance. This support helping them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.

For further information, please contact:

Tony Jones, CEO

Email: Tony@onenucleus.com
Tel: +44 (0)1223 896463
Web: www.onenucleus.com

Email: pr@adventls.com
Tel:+44 (0)20 7932 2100
Web: www.adventls.com

 

Back